ROME (ITALPRESS) – “The safety of the administration of Vaxzevria in subjects under the age of 60 remains an open topic, and on which there are margins of uncertainty”, however the Haemostasis and Thrombosis Working Group appointed by AIFA believes that “the completion of the vaccination schedule represents the strategy to combat the spread of the SARS-Cov-2 virus which guarantees the best level of protection”. This is what emerges from a document published by Aifa. The Italian Medicines Agency reminds that following the report, in subjects undergoing anti-SARS-CoV-2 vaccination with the viral vector vaccines Vaxzevria (ChAdOx1 nCov-19 from Astra Zeneca) and Janssen (Ad.26.COV2. S of the Johnson & Johnson company), of thrombotic events in atypical sites (thrombosis of the cerebral venous sinuses and / or of the splanchnic district), associated with thrombocytopenia and with clinical courses of particular severity, has appointed a group of experts in coagulation pathologies (Hemostasis and Thrombosis Working Group) in support of the Technical Scientific Commission (CTS). The mandate of the group, we read in the note, was to investigate the biological plausibility of the events, identify any risk minimization strategies and indicate the most correct modalities for the clinical management of these very rare events. The document (structured in questions and answers) represents “the conclusions of the group of experts and is aimed at providing non-specialist doctors and healthcare personnel with the information currently available to identify early and manage this very rare adverse event in the most appropriate way” . “The careful pharmacovigilance activity already in place – finally reads the document – will allow the collection of updated data and establish the possible need to formulate further recommendations aimed at optimizing, where appropriate, the benefit / risk profile in the individual patient”. “The use of the most commonly available antithrombotic drugs – namely acetylsalicylic acid (ASA), unfractionated heparin (ENF) and low molecular weight heparins (LMWH) – is associated with a modest, but not negligible, increased risk of bleeding “, therefore” the prescription of antithrombotic drugs for preventive purposes in vaccinated subjects is strongly discouraged “, Aifa emphasizes, concluding that” in the particular setting of vaccination with Vaxzevria it cannot be excluded that a subject who has not developed the rare reaction involving platelets with the first dose cannot do so with the second “. (ITALPRESS). fsc / com 26-May-21 19:54
COPYRIGHT today © breaking latest news